Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.45 |
| ▸ | NFE2 | Q16621 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1612524 | 0.91 | ALDH1A1 (0.49) | NPSR1ALDH1A1POLBSMN1; SMN2HPGD | |
| SCHEMBL1493293 | 0.85 | ALDH1A1 (0.51) | NPSR1ALDH1A1POLBSMN1; SMN2HPGD | |
| SCHEMBL1611686 | 0.82 | ALDH1A1 (0.44) | NPSR1ALDH1A1POLBSMN1; SMN2HPGD | |
| SCHEMBL1610586 | 0.82 | ALDH1A1 (0.44) | NPSR1ALDH1A1SMN1; SMN2HPGDKMT2A | |
| SCHEMBL1611415 | 0.81 | ALDH1A1 (0.59) | NPSR1ALDH1A1POLBTSHRSMN1; SMN2 | |
| SCHEMBL1493372 | 0.80 | ALDH1A1 (0.55) | ALDH1A1TSHRSMN1; SMN2NTRK1NTRK2 | |
| SCHEMBL1610585 | 0.80 | ALDH1A1 (0.52) | NPSR1ALDH1A1TSHRSMN1; SMN2HPGD | |
| SCHEMBL1493454 | 0.77 | ALDH1A1 (0.53) | ALDH1A1TSHRSMN1; SMN2NTRK1NTRK2 | |
| SCHEMBL1493590 | 0.76 | ALDH1A1 (0.51) | NPSR1ALDH1A1POLBTSHRSMN1; SMN2 | |
| SCHEMBL1493457 | 0.76 | ALDH1A1 (0.61) | NPSR1ALDH1A1TSHRSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | claimed |
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | disclosed |
| EP-2288603-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009150614-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | NPSR1 9/4885ALDH1A1 3233/4885POLB 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.